Clinical trial
Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Participants (Age 12 to <18 Years) With Homozygous Familial Hypercholesterolemia (SPRUCE)
NCT07473843 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Single-Arm Open-Label Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent Participants (Age 12 to <18 Years) With Homozygous Familial Hypercholesterolemia (SPRUCE)
- Lead sponsor
- Arrowhead Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- August 31, 2028
- Enrollment
- 10 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.